Table 3.
Clinical findings where ≥50% of patients report the finding.
| Clinical Impairment | Pre-Infection | 95% CI | Post-Infection | 95% CI |
|---|---|---|---|---|
| Attention span | ||||
| Sustained attention | 7% | (2–12%) | 84% | (77–91%) |
| Distracted by frustration | 7% | (2–12%) | 79% | (71–87%) |
| Allocation of attention | 6% | (1–11%) | 66% | (57–75%) |
| Hypersensitivity to sound | 3% | (0–6%) | 66% | (57–75%) |
| Hypersensitivity to light | 2% | (0–5%) | 63% | (54–72%) |
| Memory | ||||
| Working memory | 3% | (0–6%) | 78% | (70–86%) |
| Recent memory | 5% | (1–9%) | 77% | (69–85%) |
| Memory retrieval | ||||
| Words | 3% | (0–6%) | 70% | (62–78%) |
| Names | 6% | (1–11%) | 68% | (60–76%) |
| Numbers | 3% | (0–6%) | 52% | (43–61%) |
| Processing | ||||
| Fluency of speech | 4% | (0–8%) | 62% | (54–70%) |
| Reading comprehension | 6% | (1–11%) | 59% | (50–68%) |
| Spelling errors | 8% | (3–13%) | 56% | (47–65%) |
| Word substitution errors | 5% | (1–9%) | 55% | (46–64%) |
| Optic ataxia | 1% | (0–3%) | 51% | (42–60%) |
| Calculation | 10% | (4–16%) | 51% | (43–59%) |
| Executive functioning | ||||
| Brain fog | 3% | (0–6%) | 84% | (78–90%) |
| Unfocused concentration | 4% | (0–8%) | 81% | (75–87%) |
| Prioritizing multiple tasks | 6% | (1–11%) | 76% | (69–83%) |
| Multitasking | 3% | (0–6%) | 74% | (67–81%) |
| Mental apathy | 4% | (0–8%) | 72% | (65–79%) |
| Obsessive thoughts | 4% | (0–8%) | 56% | (48–64%) |
| Racing thoughts | 1% | (0–3%) | 54% | (46–62%) |
| Abstract reasoning | 3% | (0–6%) | 51% | (43–59%) |
| Emotional | ||||
| Decreased frustration tolerance | 5% | (1–9%) | 80% | (74–86%) |
| Sudden mood swings | 3% | (0–6%) | 74% | (67–81%) |
| Anhedonia | 3% | (0–6%) | 64% | (57–71%) |
| Crying spells | 0% | (0–0%) | 50% | (42–58%) |
| Dissociative symptoms | ||||
| Depersonalization | 2% | (0–5%) | 64% | (57–71%) |
| Behavioral | ||||
| Decreased job/school performance | 2% | (0–5%) | 78% | (72–84%) |
| Decreased social functioning | 6% | (1–11%) | 72% | (65–79%) |
| Compensatory compulsions | 2% | (0–5%) | 58% | (51–65%) |
| Dropping objects | 2% | (0–5%) | 52% | (45–59%) |
| Psychiatric syndromes | ||||
| Depression | 9% | (3–15%) | 79% | (73–85%) |
| Generalized anxiety disorder | 3% | (0–6%) | 53% | (46–60%) |
| Vegetative | ||||
| Energy | ||||
| Fatigue | 1% | (0–3%) | 76% | (70–82%) |
| Sleep | ||||
| Non-restorative sleep | 4% | (0–8%) | 76% | (70–82%) |
| Insomnia | ||||
| Hypersomnia | 2% | (0–5%) | 73% | (67–79%) |
| Insomnia, mid | 1% | (0–3%) | 72% | (66–78%) |
| Insomnia, initial | 5% | (1–9%) | 70% | (64–76%) |
| Insomnia, late | 1% | (0–3%) | 58% | (51–65%) |
| Loss of circadian rhythm | 5% | (1–9%) | 44% | (37–51%) |
| Sexual functioning | ||||
| Decreased libido | 4% | (0–8%) | 60% | (54–66%) |
| Temperature control | ||||
| Intolerance to cold | 2% | (0–5%) | 64% | (58–70%) |
| Body temperature fluctuations | 3% | (0–6%) | 63% | (57–69%) |
| Night sweats | 2% | (0–5%) | 60% | (54–66%) |
| Intolerance to heat | 2% | (0–5%) | 58% | (52–64%) |
| Decreased body temperature | 5% | (1–9%) | 52% | (46–58%) |
| Chills | 2% | (0–5%) | 59% | (53–65%) |
| Neurological | ||||
| Headache | 3% | (0–6%) | 68% | (62–74%) |
| Tension headache | 2% | (0–5%) | 57% | (51–63%) |
| Cranial nerves | ||||
| II Optic (and ophthalmologic) | ||||
| Photophobia to bright light | 3% | (0–6%) | 61% | (55–67%) |
| Floaters | 1% | (0–3%) | 56% | (50–62%) |
| Dizziness | 2% | (0–5%) | 53% | (47–59%) |
| VIII Tinnitus | 1% | (0–3%) | 51% | (45–57%) |
| Blurred vision | 2% | (0–5%) | 50% | (44–56%) |
| Other neurological | ||||
| Numbness | 1% | (0–3%) | 59% | (53–65%) |
| Tingling | 1% | (0–3%) | 71% | (66–76%) |
| Paresis | 2% | (0–5%) | 66% | (61–71%) |
| Tremor | 3% | (0–6%) | 40% | (34–46%) |
| Twitching | 1% | (0–3%) | 56% | (50–62%) |
| Muscle tightness | 0% | (0–0%) | 56% | (50–62%) |
| Restless leg | 5% | (1–9%) | 50% | (44–56%) |
| Musculoskeletal | ||||
| Joint pain, swelling, tightness, and crepitation (specify joints) | 2% | (0–5%) | 81% | (77–85%) |
| Myalgia | 1% | (0–3%) | 54% | (49–59%) |
| Gastrointestinal | ||||
| Irritable bowel | 6% | (1–11%) | 50% | (45–55%) |
| Symptom pattern | ||||
| Progression of symptoms | 0% | (0–0%) | 86% | (79–93%) |
| Fluctuation of symptoms | 0% | (0–0%) | 82% | (74–90%) |
| Stress increased symptoms | 0% | (0–0%) | 77% | (69–85%) |
| Herxheimer reaction | 0% | (0–0%) | 73% | (64–82%) |
| Antibiotic reduce symptoms | 0% | (0–0%) | 72% | (63–81%) |